Logo image
Intramuscular Interferon Beta-1A Therapy Initiated during a First Demyelinating Event in Multiple Sclerosis
Journal article   Open access   Peer reviewed

Intramuscular Interferon Beta-1A Therapy Initiated during a First Demyelinating Event in Multiple Sclerosis

Lawrence D Jacobs, Roy W Beck, Jack H Simon, R. Phillip Kinkel, Carol M Brownscheidle, Thomas J Murray, Nancy A Simonian, Peter J Slasor, Alfred W Sandrock and the CHAMPS Study Group
The New England Journal of Medicine, Vol.343(13), pp.898-904
09/28/2000
DOI: 10.1056/NEJM200009283431301
PMID: 11006365
url
https://doi.org/10.1056/NEJM200009283431301View
Published (Version of record) Open Access

Abstract

Multiple sclerosis is a chronic, inflammatory, demyelinating disease of the central nervous system that most commonly affects women, with an onset typically between 20 and 40 years of age. A diagnosis of clinically definite multiple sclerosis requires the occurrence of at least two neurologic events consistent with demyelination that are separated both anatomically in the central nervous system and temporally. 1 Magnetic resonance imaging (MRI) of the brain, by identifying lesions consistent with the occurrence of demyelination, can add certainty to the diagnosis. 2 , 3 The presence of such MRI-identified lesions in a patient with an isolated syndrome of the optic nerve . . .

Details

Metrics

Logo image